Supriya Lifescience has received the World Health Organization’s Good Manufacturing Practices (WHO GMP) certification for its Ambernath manufacturing facility.

The site is equipped for manufacturing injectables, tablets, capsules, and inhalation dosage forms, with a projected peak revenue potential of approximately INR 500 crore. The company expects this segment to deliver higher margins compared to its Active Pharmaceutical Ingredient (API) business.

According to the company’s FY 2024-25 annual report, capacity expansion at Ambernath was among its key strategic priorities. With the WHO GMP approval now secured, the facility is eligible to supply formulations to WHO-listed agencies and regulated international markets—a development that advances Supriya’s formulations roadmap. Together with its Lote Parshuram API unit, the company’s total manufacturing capacity now exceeds 1,020 KL, enhancing operational flexibility and asset utilisation.

Commenting on the achievement, Dr. Satish Wagh, Executive Chairman and Whole-Time Director, said, “The WHO GMP certification for Ambernath is a defining milestone for Supriya Lifescience. It reaffirms our commitment to global quality standards and opens up opportunities to scale our formulations business through a world-class facility. This progress strengthens our international presence and positions us for sustainable growth in higher-margin therapeutic segments.”

In addition to commercial production, the Ambernath facility houses R&D and pilot-scale operations, and supports Contract Development and Manufacturing (CDMO/CMO) services.